Evidence map›Paper›PMID 39868839›Full record

ArticleClinical pharmacology and therapeutics2025

Investigation of Genomic and Transcriptomic Risk Factors of Clopidogrel Response in African Americans.

Guang Yang, Cristina Alarcon, Catherine Chanfreau, Norman H Lee, Paula Friedman, Edith Nutescu, Matthew Tuck, Travis O'Brien, Li Gong, Teri E Klein and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Recent research progress on the mechanisms of clopidogrel resistance.European journal of clinical pharmacology · 2026
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Guang YangDepartment of Pharmacology, Center for Pharmacogenomics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0003-2920-6523
Cristina AlarconDepartment of Pharmacology, Center for Pharmacogenomics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Catherine ChanfreauVA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0002-4663-8953
Norman H LeeDepartment of Pharmacology and Physiology, George Washington University, Washington, DC, USA.
Paula FriedmanDepartment of Pharmacology, Center for Pharmacogenomics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Edith NutescuDepartment of Pharmacy Practice, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.
Matthew TuckWashington DC VA Medical Center, Washington, DC, USA.
Travis O'BrienDepartment of Pharmacology and Physiology, George Washington University, Washington, DC, USA.
Li GongDepartment of Biomedical Data Science, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0002-1739-8233
Teri E KleinDepartment of Biomedical Data Science and Department of Medicine, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0001-5527-6475
Kyong-Mi ChangCorporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA.
Philip S TsaoVA Palo Alto Healthcare System and Stanford University, Palo Alto, California, USA.
David O MeltzerSection of Hospital Medicine, Department of Medicine, University of Chicago, Chicago, Illinois, USA.
Julie A LynchVA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0003-0108-2127
Million Veteran Program
Sony TutejaCorporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-7007-3289
Minoli A PereraDepartment of Pharmacology, Center for Pharmacogenomics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-1146-2791

Funding

BLRD VA I01 BX003362
6 · The paper itself

Abstract

Clopidogrel, an anti-platelet drug, is used to prevent thrombosis after percutaneous coronary intervention. Clopidogrel resistance results in recurring ischemic events, with African Americans (AA) suffering disproportionately. The aim of this study was to discover novel biomarkers of clopidogrel resistance in African Americans using genome and transcriptome data. We conducted a genome-wide association study (GWAS), including local ancestry adjustment, in 141 AA on clopidogrel to identify genetic associations with high on-treatment platelet reactivity (HTPR), with validation of genome-wide significant and suggestive loci in an independent cohort of AA clopidogrel patients (N = 823) from the Million Veteran's Program (MVP) along with in vitro functional analysis. We performed differential gene expression (DGE) analysis in whole blood to identify transcriptomic predictors of response, followed by functional validation in MEG-01 cells. GWAS identified one signal on Chromosome 7 as significantly associated with increasing risk of HTPR. The lead single-nucleotide polymorphism (SNP), rs7807369, within thrombospondin 7A (THSD7A) was associated with an increased risk of HTPR (odds ratio (OR) = 4.02, P = 4.56 × 10

Indexed as

Black or African AmericanClopidogrelDrug ResistancePlatelet Aggregation InhibitorsTranscriptomeAgedFemaleGenome-Wide Association StudyHumansMaleMiddle AgedPharmacogenomic VariantsPolymorphism, Single NucleotideRisk FactorsThrombospondinsClopidogrelPlatelet Aggregation InhibitorsThrombospondins

Identifiers

PMID39868839
PMCPMC11993291

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.